Maziar Doustdar - Novo Nordisk Head VP
| NOVA Stock | EUR 80.40 19.20 19.28% |
Insider
Maziar Doustdar is Head VP of Novo Nordisk AS
| Age | 53 |
| Phone | 45 44 44 88 88 |
| Web | https://www.novonordisk.com |
Novo Nordisk Management Efficiency
The company has return on total asset (ROA) of 0.2169 % which means that it generated a profit of $0.2169 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.72 %, meaning that it generated $0.72 on every $100 dollars invested by stockholders. Novo Nordisk's management efficiency ratios could be used to measure how well Novo Nordisk manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Charles Wagner | Vertex Pharmaceuticals Incorpor | 55 | |
| BS BS | CSL Limited | 61 | |
| Ryan Richardson | BioNTech SE | 44 | |
| Robert Langer | Moderna | 73 | |
| Susie Lisa | Vertex Pharmaceuticals Incorpor | N/A | |
| Paul BA | CSL Limited | 66 | |
| Sabine Kohleisen | Mercedes Benz Group AG | 59 | |
| Lavina CFA | Moderna | N/A | |
| Paul McKenzie | CSL Limited | 57 | |
| Jeffrey MD | Vertex Pharmaceuticals Incorpor | 67 | |
| MS BA | CSL Limited | 53 | |
| Jorg Burzer | Mercedes Benz Group AG | 53 | |
| Mark Dehring | CSL Limited | N/A | |
| Jens Holstein | BioNTech SE | 60 | |
| Elizabeth Tallett | Moderna | 70 | |
| Damian Esq | Vertex Pharmaceuticals Incorpor | 47 | |
| Tal Zaks | Moderna | 53 | |
| BCom BComm | CSL Limited | 57 | |
| Paul Sagan | Moderna | 59 | |
| Stephen Berenson | Moderna | 58 | |
| Sean Marett | BioNTech SE | 58 | |
Management Performance
| Return On Equity | 0.72 | |||
| Return On Asset | 0.22 |
Novo Nordisk AS Leadership Team
Elected by the shareholders, the Novo Nordisk's board of directors comprises two types of representatives: Novo Nordisk inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novo. The board's role is to monitor Novo Nordisk's management team and ensure that shareholders' interests are well served. Novo Nordisk's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novo Nordisk's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Monique Carter, Head VP | ||
| Maziar Doustdar, Head VP | ||
| Lars Jorgensen, CEO Pres | ||
| Marcus Schindler, Head EVP | ||
| Karsten Knudsen, CFO VP | ||
| Henrik Wulff, Head VP | ||
| Ludovic Helfgott, Head VP | ||
| Camilla Sylvest, Head VP | ||
| Douglas Langa, Head VP | ||
| Martin Lange, Head VP |
Novo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Novo Nordisk a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.72 | |||
| Return On Asset | 0.22 | |||
| Profit Margin | 0.31 % | |||
| Operating Margin | 0.43 % | |||
| Current Valuation | 282.15 B | |||
| Shares Outstanding | 2.25 B | |||
| Shares Owned By Insiders | 0.01 % | |||
| Shares Owned By Institutions | 8.34 % | |||
| Price To Earning | 17.63 X | |||
| Price To Book | 27.50 X |
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Novo Stock
When determining whether Novo Nordisk AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Novo Nordisk's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Novo Nordisk As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Novo Nordisk As Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .